SEC Filing | Quoin Pharmaceuticals, Inc.

View:

Download DOC

Download PDF

Download XLS

Filed pursuant to Rule 424(b)(3)
SEC File No. 333-264305

PROSPECTUS SUPPLEMENT NO. 3

(to Prospectus dated April 22, 2022)

6,435,548,000 Ordinary Shares

Represented by 16,088,870 American Depositary Shares

This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1, effective as of April 22, 2022 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-264305). Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Form 6-K furnished with the Securities and Exchange Commission (the “SEC”) on June 6, 2022, which is set forth below.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Our ordinary shares are listed on the Nasdaq Capital Market under the symbol “QNRX”. On June 3, 2022, the closing price for our ordinary shares on the Nasdaq Capital Market was $0.6150 per share.

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties under the heading “Risk Factors” beginning on page 9 of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 6, 2022.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2022 (No. 1)

Commission File Number 001-37846

QUOIN PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

Azrieli Center, Round Tower, 30^th Floor

132 Menachem Begin Blvd

Tel Aviv, 6701101

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXPLANATORY NOTE

Research Agreement

Effective as of May 20, 2022, Quoin Pharmaceuticals, Inc. (“Quoin”) entered into a Research Agreement (the “Research Agreement”) with Queensland University of Technology, Australia, to collaborate on the project related to the selection of a lead VLA-4 inhibitor for entry into a Scleroderma clinical development program.

The foregoing description of the Research Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of such Research Agreement, attached hereto as Exhibit 10.1 and incorporated by reference herein.

Waiver Agreement

On June 6, 2022, Quoin Pharmaceuticals Ltd. (the “Company”) (formerly known as Cellect Biotechnology Ltd.) and Quoin entered into a Waiver Agreement (the “Waiver Agreement”) with Altium Growth Fund, LP (“Altium”), pursuant to which Altium waived certain provisions of the Securities Purchase Agreement, dated as of March 24, 2021, as amended, by and among the Company, Quoin and Altium, including permitting the Company to file a registration statement.

The foregoing description of the Waiver Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of such Waiver Agreement, attached hereto as Exhibit 10.2 and incorporated by reference herein.

The information in this Form 6-K, including the exhibits hereto, shall be incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos. 333-214817, 333-220015, 333-225003 and 333-232230) and on Form F-3 (Registration Nos. 333-219614 and 333-229083).

Exhibits

Exhibit No.	Exhibit
10.1	Research Agreement, dated May 20, 2022, by and between Quoin Pharmaceuticals, Inc. and Queensland University of Technology, Australia (certain provisions of this exhibit have been omitted pursuant to Instruction No. 4 to Exhibits in Form 20-F)
10.2	Waiver Agreement, dated June 6, 2022, by and among Quoin Pharmaceuticals Ltd., Quoin Pharmaceuticals, Inc. and Altium Growth Fund, LP

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 6, 2022	QUOIN PHARMACEUTICALS LTD.

	By:	/s/ Gordon Dunn
	Name:	Gordon Dunn
	Title:	Chief Financial Officer

Exhibit 10.1

CRICOS No. 00213J ABN 83 791 724 622

Document Classification MOPP F/1.2.5:

THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE

IT IS BOTH (i) NOT MATERIAL, AND (ii) THE TYPE THAT THE REGISTRANT

TREATS AS PRIVATE OR CONFIDENTIAL

Research Agreement

THIS AGREEMENT is made

BETWEEN	queensland university of technology (ABN 83 791 724 622) of 2 George Street, Brisbane, 4000, in the State of Queensland, Australia (“QUT”)
AND	QUOIN PHARMACEUTICALS, Inc., a Delaware corporation, with an address of 42127 Pleasant Forest Ct, Ashburn, VA 20148 USA (“Quoin” or “Collaborator”)

BACKGROUND

The parties wish to collaborate on, and provide their contributions to, the Project in accordance with the terms of this Agreement.

OPERATIVE PROVISIONS

DEFINITIONS and INTERPRETATION

1.1

In this Agreement, the following words have the following meanings:

Agreement means this document and any schedules or attachments to this document.

Background Material of a party means Materials created prior to, or independently of, this Agreement (including third party Material) which that party contributes or makes available for use in the Project, including the Material listed in Schedule 4.

Bluebox means qutbluebox Pty Ltd ABN 97 041 405 905 of Level 4, Block X, 88 Musk Avenue, Kelvin Grove, Qld 4059, being the subsidiary trustee company established by QUT to commercialise its Intellectual Property Rights.

Commencement Date means the date of complete execution of this Agreement by the Parties.

Commercialise means to exercise or deal with the Intellectual Property Rights in Material, in any way for a financial gain or benefit (whether or not such gain or benefit is ultimately obtained) including:

(a)

to exercise Intellectual Property Rights in the Material to provide a service for which a financial gain or benefit is received;

(b)

to exercise Intellectual Property Rights in the Material to create, or as part of, a product or process which is, or is to be, sold, hired, leased, distributed or made available to others for financial gain or benefit;

(c)

to directly or indirectly grant to others rights to use Intellectual Property Rights in the Material for a financial gain or benefit,

but does not include the use of the Material in connection with delivering award courses or to undertake public benefit or other non-commercial research with or without funding from a third party and Commercialisation shall have a corresponding meaning.

Confidential Information of a party means:

(a)

any information designated as that party’s Confidential Information in Schedule 4;

(b)

any new information generated as part of Project Material in which that party owns the Intellectual Property Rights; and

(c)

any information developed independently of this Agreement (whether by the party or a third party), that the party makes available to the other party for the purposes of this Agreement including the conduct of the Project which that party designates as confidential or the receiving party ought reasonably know is confidential from the circumstances or nature of the information,

but does not include information which is:

(d)

publicly available or subsequently becomes publicly available other than in breach of this Agreement;

(e)

lawfully known to another party on a non-confidential basis before being disclosed by the other party; or

(f)

lawfully acquired by another party on a non-confidential basis from a third party without breaching obligations of confidentiality.

Contributions means the cash and in-kind contributions to be made by a party as specified in Schedule 3.

Expiration Date means the conclusion of the Project as described in Schedule 2.

Force Majeure Event with respect to a party means an unforeseeable event beyond the control of an affected party which occurs without fault or negligence of the affected party (but shall not include non-performance of any Specified Personnel) including:

(a)

acts of God;

(b)

war, riot, insurrection, vandalism or sabotage;

(c)

strike, lockout, ban, limitation of work or other industrial disturbance; and

(d)

law, rule or regulation of any government or governmental agency and executive or administrative order or act of general or particular application.

Intellectual Property Rights or IPRs includes any and all intellectual and industrial property rights throughout the world however conferred by statute, common law or equity in any jurisdiction including rights in respect of or in connection with:

(a)

(b)

plant varieties;

(c)

inventions (including patents and any divisionals, continuations, continuation-in-parts, patent term extensions, and supplementary protection certificates thereto),

(d)

confidential information, trade secrets and know-how;

(e)

trade marks, service marks;

(f)

designs, circuit layouts; and

any other results of intellectual activity in the industrial, commercial, scientific or literary or artistic fields, whether or not now existing and whether or not registered or registrable and includes any rights to apply for the registration of such rights and includes all renewals and extensions.

Key Terms means the key terms described in clause 9.4 which must be included in an agreement described in clause 9.1.

Material means any ideas, discoveries, inventions, information, data, compilations, records, designs, works, technology, software, methods, processes, formulas, names, logos or any other thing of any kind in which Intellectual Property Rights or other rights subsist.

Option means the exclusive option described in clause 9.1 of this Agreement.

Option Period shall be from the Commencement of this Agreement until the earlier of the following:

(a)

Six (6) months after the conclusion of the Project under this Agreement;

(b)

Execution of an agreement described in clause 9.1 of this Agreement;

(c)

Termination of this Agreement under clause 16.2.

Project means the project described in Schedule 2.

Personal Information means information or an opinion, including information or an opinion forming part of a database, whether true or not, and whether recorded in a material form or not, about an individual whose identity is apparent, or can reasonably be ascertained, from the information or opinion.

Personnel of a party means the employees, contractors, students and any other person that is an agent of that party.

“Post Doc” means the post doctorial candidate hired by QUT and included as QUT’s Specified Personnel in connection with the terms of this Agreement.

Project Material means all Material created in connection with the Project by a party’s Personnel. For the avoidance of doubt Project Material does not include Background Material incorporated in the Project Material.

Specified Personnel are those Personnel of a party listed in Schedule 2.

Term is defined in clause 2.1.

1.2

In this Agreement:

(a)

a right to ‘use’ Material includes any use that requires the exercise of Intellectual Property Rights in that Material;

(b)

the singular includes the plural and vice versa;

(c)

a reference to a gender includes the other genders;

(d)

headings are for reference only and do not affect the meaning of any provision;

(e)

other grammatical forms of each defined word or expression will have a corresponding meaning;

(f)

a reference to this Agreement includes any schedules or annexures to this Agreement;

(g)

a reference to a clause, paragraph, schedule or annexure is a reference to a clause or paragraph of or schedule or annexure to this Agreement;

(h)

a reference to a document or agreement, including a reference to this Agreement, includes a reference to that document or agreement as novated, varied or replaced from time to time;

(i)

a reference to “$”, “$A”, “dollar” or “A$” is a reference to Australian currency;

(j)

a reference to a month is a reference to a calendar month;

(k)

a reference to a person includes a reference to bodies corporate, partnerships, incorporated and unincorporated associations, firms, joint ventures, trusts, governments and governmental and semi-governmental bodies;

(l)

a reference to any legislation, regulation or other statutory instrument includes a reference to any enactment, amendment, substitution or consolidation and any statutory instrument issued pursuant to such legislation, regulation or other statutory instrument;

(m)

a reference to writing includes all physical and electronic methods of visibly representing or reproducing words, figures or symbols;

(n)

no rule of construction applies to the disadvantage of the party that drafts this Agreement on the basis that the party suggested the relevant drafting;

(o)

words such as “includes” and “including” do not impose any limitation on the construction of general language that is followed by specific examples.

1.3

In the event of any inconsistency between any of the provisions of this Agreement, they shall take precedence in the following order:

(a)

the terms and conditions (with primary obligations taking precedence);

(b)

the schedules; and

(c)

any other document attached or incorporated by reference.

TERM

2.1

Except in relation to the Option and all terms relevant to it, this Agreement commences on the Commencement Date and ends on the Expiration Date unless terminated earlier in accordance with this Agreement (Term).

2.2

Prior to the expiry of the Agreement, the parties may extend the Term by written agreement. Any agreement to such extension is made in each party’s absolute discretion and subject to internal approval.

CONDUCT OF PROJECTS

3.1

The parties agree to participate in the Project:

(a)

as specified in Schedule 2 and this Agreement;

(b)

diligently, competently and in accordance with the professional, scientific, ethical, business and financial principles and standards that would be reasonably expected to apply to such work; and

(c)

in accordance with applicable laws.

(d)

Notwithstanding the foregoing, it is acknowledged that all research is being performed by QUT through its Specified Personnel. QUT shall perform (and cause is Specified Personnel to perform) the Project consistent with subpart (b) above, by qualified personnel and in accordance with accepted scientific and ethical principles, standards and laboratory procedures and consistent with (i) effort and at a quality comparable to research performed at major public and private research universities (including within the United States and Australia) and (ii) applicable laws. QUT shall obtain (and require its Specified Personnel and approved sub-contractors to obtain) all required licenses, permits regulatory or ethics approval before carrying out activities under this Agreement.

3.2

The parties will not be liable to perform the Project until they have those approvals specified in Schedule 2 (if any) for the Project and upon such approvals being obtained any affected Project timeframes will be extended accordingly. The parties agree to cooperate and use all reasonable endeavours to obtain all necessary approvals in a timely manner.

3.3

With Quoin’s prior approval, QUT may engage a subcontractor to perform work in relation to the Project, provided that such subcontract shall include terms no less onerous than provided in this Agreement. QUT also vouches that the subcontractor is fully qualified to perform such work. Without limiting the foregoing, QUT shall be solely responsible for its performance under this Agreement and for any work sub-contracted to any third party (it being agreed that, notwithstanding anything contained in this Agreement to the contrary, any breach by subcontractors or its Specified Personnel or their respective affiliates (including Bluebox) of this Agreement shall be deemed a breach by QUT of this Agreement). All work sub-contracted to third party shall only be on work-for-hire basis and such third parties shall have no right to any Project Material or IPRs used or developed in connection with work performed.

DAY TO DAY MANAGEMENT; REPORTS

4.1

The parties will keep each other informed of the progress of the Project in writing and by telephone and will, from time to time:

(a)

discuss the progress of the Project;

(b)

facilitate the review and approval of publications in respect of the Project;

(c)

identify potential registrable or commercially valuable IPRs arising from the Project and promptly notify the parties in relation to any protectable or commercially valuable IPR; and

(d)

discuss in good faith any issues that may arise during the course of this Agreement in relation to the Project.

(e)

Without limiting the generality of above, QUT shall cause its Specified Personnel to issue a detailed written final report to Quoin summarizing the results of the Project, including Project Material, if any, within thirty (30) days after completing the Project. In addition to the above final report, within thirty (30) days after each milestone payment set forth on Schedule 3 is made, QUT shall cause its Specified Personnel to provide to Quoin interim written reports giving status of the Project, and the results and activities carried out prior to such milestone payment date. During the Term, QUT shall (and shall cause the QUT Specified Personnel and subcontractors) to (x) permit Quoin and its representatives to have at least one in person meeting with QUT and the Specified Personnel at QUT’s facility on an annual basis,, and (y) make available the Specified Personnel and applicable employees of QUT as requested by Quoin.

4.2

Despite the discussions between the parties under this Agreement, no variations shall be made to the Agreement except in writing signed by the parties.

4.3

For the purpose of this clause, Bluebox may engage in discussions as the agent of QUT, subject to the terms and conditions set forth herein.

CONTRIBUTIONS

Cash Contributions

5.1

QUT will issue the Collaborator with GST compliant invoices for their respective cash Contributions in the amounts and at the times specified in Schedule 3.

5.2

The Collaborator must pay the amounts invoiced in accordance with clause 5.1 by the due date specified in the invoice (which will be no less than 45 days from the date of invoice).

5.3

QUT will use the cash Contributions for the Project in accordance with the Budget.

5.4

If the Parties agree that QUT shall use any cash Contributions to purchase equipment for the Project, then that equipment will be owned by QUT, unless the parties have expressly agreed otherwise in writing.

In-Kind Contributions

5.5

The parties will make their in-kind Contributions to the Project to the value and for the time contemplated in Schedule 3.

SPECIFIED PERSONNEL.

6.1

Each party acknowledges that any of its Personnel named as Specified Personnel in this Agreement, must be directed to work on the Project for the times specified in this Agreement and if at any time they are unable to do so, then that party must:

(a)

immediately notify the other party of the unavailability; and

(b)

promptly replace that Specified Personnel with personnel who have:

(1)

the time commitment, qualifications and competency to carry out the Project; and

(2)

similar expertise and ability to those of the Specified Personnel they are to replace; and

(c)

notify the other party of the name and qualifications of the replacement personnel upon finding a replacement.

BACKGROUND MATERIAL

7.1

Nothing in this Agreement alters or transfers ownership in any Background Material, including any Intellectual Property Rights subsisting in Background Material.

7.2

Each party grants to each other party a non-exclusive, royalty-free licence to use its Background Material:

(a)

during the Term - for the purpose of carrying out the Project in accordance with this Agreement; and

(b)

during and after the Term - in conjunction with Project Material for purposes other than Commercialisation which are solely for research or academic purposes and only to the extent the Background Material is necessary for the other party to exercise the full benefit of the rights in the Project Material granted to it under this Agreement,

BUT subject to the confidentiality obligations herein and any restrictions or obligations made known to the other party prior to that Background Material being used in the Project.

7.3

For the avoidance of doubt, no rights are given to a party to sublicense any rights in Background Material to a third party.

PROJECT MATERIAL

8.1

All Intellectual Property Rights in Project Material made by QUT shall vest in QUT. All Intellectual Property Rights in Project Material made by Quoin shall vest in Quoin. All Intellectual Property Rights in Project Material made jointly by QUT and Quoin shall jointly vest in QUT and Quoin.

8.2

The parties each grant a non-exclusive, royalty-free licence in the Project Materials that they own to the other party for the performance of the Project and for internal - non-commercial research and teaching purposes.

8.3

No party may unlawfully use the Project Material in which another party owns enforceable Intellectual Property Rights except as expressly specified in this Agreement or in compliance with the written consent of that other party.

OPTION TO COMMERCIALISE

9.1

QUT grants the Collaborator an exclusive Option to enter into an agreement, which will be negotiated by the parties hereto in good faith, for the exclusive Commercialisation of the Project Materials in accordance with clause 9.3.

9.2

Subject to full payment of cash Contributions under this Agreement, the Collaborator may at any time during the Option Period exercise the Option by giving QUT written notice of the exercise of the Option.

9.3

The agreement described in clause 9.1 shall be subject to the following:

(a)

On exercise of the Option in accordance with clause 9.2, the parties must commence negotiation of the terms of the agreement within thirty (30) business days of receiving the notice to exercise the Option;

(b)

The terms of the agreement described in clause 9.1 must incorporate the Key Terms and be negotiated on an arms-length commercial basis;

(c)

If the parties have failed to agree on the Key Terms of the agreement described in clause 9.1 within six (6) months of the exercise of the Option, then QUT may Commercialise the Project Materials as QUT sees fit;

(d)

If the Project Materials are commercialised by someone other than the Collaborator under clause 9.3(c), the Collaborator will be entitled to a 10% royalty of all revenue received by QUT from the Commercialisation of the Project Materials up to a maximum amount equal to the total payments made by the Collaborator to QUT under this Agreement; and,

(e)

The parties must act reasonably in negotiating the agreement described in clause 9.1.

9.4

The Key Terms which must be included in an agreement described in clause 9.1 are as follows:

(a)

The scope of Intellectual Property Rights that will be the subject of agreement under the Option shall be the Project Materials owned or controlled by QUT and created in the course of the Project which may be relevant for treatment of Scleroderma and includes:

(1)

Composition of matter of the small molecule inhibitors that disrupt the VCAM-1:VLA-4 interaction, pharmaceutical compositions containing it, methods of using them, and processes for making them;

(2)

Data relating to activity of the small molecule inhibitors ;

(3)

Know how in relation to the preparation and use of the small molecule inhibitors ;

(4)

Rights to apply for and register patents in relation to the small molecule inhibitors , pharmaceutical compositions containing it, methods of using them, and processes for making them worldwide, including in Australia and in all other countries.

(b)

The agreement may include either an assignment or exclusive license of the Intellectual Property Rights which are the subject of the agreement;

(c)

There must be a royalty rate in the range of 3% to 5%.

(d)

There may be milestone payments which shall, at a minimum, relate to the costs of any intellectual property protection or other steps taken by QUT in relation to the Intellectual Property Rights the subject of the agreement;

(e)

The field of commercialisation shall be use as a therapeutic for any indication.

(f)

The territory for the arrangement will be world-wide.

(g)

The arrangement must be exclusive within the field of commercialisation and within the territory.

9.5

If either:

(a)

the Collaborator does not exercise the Option within sixty (60) Business Days of the expiry of the Option Period; or,

(b)

the parties do not execute an agreement as described in clause 9.1 within six (6) months of the exercise of the Option,

then the Option will automatically terminate and be exhausted and this clause shall no longer have force or effect.

9.6

The Collaborator acknowledges that QUT manages the protection and Commercialisation of QUT generated Intellectual Property Rights via Bluebox, and that negotiations in relation to the protection and Commercialisation of Project Material and Background Material may therefore be between the Collaborator and Bluebox.

INTELLECTUAL PROPERTY RIGHTS PROTECTION

10.1

During the Term, QUT (including by its agent, Bluebox) shall prosecute and maintain all current Intellectual Property Rights in the Project Materials solely made by QUT or jointly made by QUT and Quoin (“Project Inventions”) and may make additional applications as it considers commercially and legally responsible.

10.2

During the Term, QUT (including by its agent, Bluebox) shall be responsible for the costs of all filling, maintenance and prosecution of Intellectual Property Rights in the Project Inventions. QUT (including by its agent, Bluebox) shall keep the Collaborator informed of the status of any patent applications made in relation to the Project Materials from time to time and on request.

10.3

In the event that QUT does not elect to file, maintain or prosecute Intellectual Property Rights in the Project Materials, the Collaborator will have the right, at its sole discretion and sole expense, to take action to file, maintain or prosecute Intellectual Property Rights in the Project Inventions. Any Intellectual Property Rights filed, maintained or prosecuted by the Collaborator under this sub-clause must be in the name of QUT if solely made by QUT, or in the name of QUT and Quoin if jointly made by QUT and Quoin, until an agreement under clause 9.1 of this Agreement is executed.

10.4

In the event the Collaborator exercises the Option and the parties enter into an agreement described in clause 9.1, the Collaborator shall be responsible for all future Intellectual Property Rights patent applications, maintenance and prosecution dealt with in that agreement. QUT (including by its agent, Bluebox) agree to provide the Collaborator with all reasonable assistance for the Collaborators filings, maintenance and prosecutions under this clause, subject to the Collaborator paying any out of pocket expenses incurred by QUT (or its agent, Bluebox) in providing such assistance.

CONFIDENTIALITY

11.1

Each party must:

(a)

maintain the secrecy of, and prevent unauthorised access to, each other's Confidential Information;

(b)

not use another's Confidential Information except:

(1)

as required for the performance of, or to exercise its rights under or arising from, this Agreement; or

(2)

as required to obtain professional advice in relation to any matter connected with this Agreement including advice on the patenting of Project Material;

(c)

not disclose another's Confidential Information to any person other than to:

(1)

its Personnel who need to know it in order to perform the Project, or in order to exercise the party’s rights in Material under this Agreement or the Option Agreement; and

(2)

its professional advisors with a need to know it in order to provide professional advice in relation to any matter connected with this Agreement including advice on the patenting of Project Material; and

(d)

ensure that its Personnel and advisors to whom the other’s Confidential Information is disclosed, are made aware of the obligations of confidentiality under this Agreement, and are legally obliged to ensure that the Confidential Information is only used, disclosed and dealt with in accordance with those obligations.

11.2

Each party may disclose another party’s Confidential Information if required by law but, unless prohibited by law or legal process, it must inform that other party first (with as much prior notice as possible) and use all reasonable endeavours to limit the terms of that disclosure as reasonably requested by that other party.

PRIVACY

12.1

Each party must, in dealing with any Personal Information for the purposes of the Project:

(a)

comply with all laws applicable to that party (including, without limitation, privacy and data protection laws) which regulate the collection, storage, use and disclosure of Personal Information;

(b)

promptly notify the other party of any complaint or investigation under, or relating to, any breach of those laws in relation to that information processed for purposes of the Project; and

(c)

reasonably cooperate with the other party in resolving any such complaint or investigation.

12.2

If a Collaborator is considered a ‘contracted service provider’ of QUT under the Information Privacy Act 2009 (Qld) in performing its obligations under this Agreement, it will comply with Parts 1 and 3 of that Act as if it were an agency under that Act.

PUBLICATIONS

13.1

The parties will ensure that all publications and presentations in respect of the Project comply with the authorship and publication requirements of the Australian Code for the Responsible Conduct of Research.

13.2

In addition to clause 13.1, each party (“Publishing Party”) must before publishing or submitting for publication, or presenting, anything in relation to the Project that discloses another party’s Confidential Information, or uses another party’s Background Material (“Publication”), provide a copy of the proposed Publication to that other party (“Reviewing Party”) for review and response in accordance with clause 13.3.

13.3

Within fourteen (14) days of the Publishing Party providing the Publication to the Reviewing Party for review, the Reviewing Party must notify the Publishing Party in writing that it:

(a)

gives unconditional consent; or

(b)

gives consent subject to certain amendments being made which are in the reasonable opinion of the Reviewing Party necessary to ensure its Confidential Information is not disclosed and its privacy obligations are met;

(c)

require the Publication to be delayed for up to 6 months so as to not prejudice its ability to protect and Commercialise its Confidential Information or other Background Material, including to exercise rights under the Option Agreement.

13.4

If the Publishing Party does not receive a response in accordance with clause 13.3 within twenty eight (28) days of the Reviewing Party receiving the Publication for review, the Reviewing Party will be deemed to have given unconditional consent.

13.5

The Publishing Party may proceed with the Publication:

(a)

upon unconditional consent being given by all Reviewing Parties; or

(b)

if amendments are required under clause (b), upon all reasonable amendments being made; and

(c)

if a period of delay is required under clause 13.3(c), upon the expiry of that period.

USE OF NAMES

14.1

Neither party may in connection with this Agreement, without the written consent of the other party, use the other party’s name or logo, or any of the other party’s Personnel’s names to promote the party’s business, services products or activities, or in a manner that could lead a person to reasonably believe that the other party endorses the party’s business, services, products or activities.

WARRANTIES AND LIABILITY

15.1

To the extent permitted by law, all terms that may be otherwise implied by statute or otherwise, relating to the subject matter of this Agreement, are excluded.

15.2

The parties acknowledge that the research undertaken as part of the Project is highly speculative in nature and may not produce any outputs or discoveries that are fit for a particular purpose or have any Commercialisation potential.

15.3

Despite any other clause of this Agreement, the parties are not liable for any indirect, consequential or incidental damages or any loss of profits, loss of revenue, loss of goodwill, loss of data, damage to reputation and loss of opportunities under or in connection with this Agreement whether under the law of contract, tort (including negligence), equity or otherwise, unless they arise from a breach of confidentiality under this Agreement or an infringement of a party’s rights in Project Material or Background Material.

15.4

Each party's liability under or in relation to this Agreement is reduced to the extent that any damages, liability, loss or costs arises from or is attributable to, any breach of contract by, or any unlawful or negligent act or omission of, the other party or the other party’s Personnel.

15.5

If any applicable legislation prohibits the exclusion of liability by a party in the manner contemplated by this clause, then:

(a)

the exclusion does not apply to that liability; and

(b)

that party’s liability is only limited or excluded in the manner permitted under that legislation (if any).

TERMINATION AND WITHDRAWAL

Termination by agreement

16.1

This Agreement may be terminated at any time by written agreement of the parties.

QUT Right to terminate the Agreement

16.2

QUT may upon by written notice to the Collaborator terminate this Agreement if the Collaborator:

(a)

breaches any warranty, term or condition of this Agreement which is not capable or remedy;

(b)

breaches a warranty, term or condition of this Agreement and fails to remedy the breach within thirty (30) days after receiving notice requiring it to do so, including with respect to any obligation to pay money or find replacement Specified Personnel; or

(c)

has entered into any form of insolvency, liquidation or external administration, whether voluntary or involuntary, formal or otherwise.

Consequences of termination or expiry of Agreement

16.3

Upon expiry or termination of this Agreement each party will, subject to that party’s statutory record keeping obligations, return (or in the case of intangible copies that cannot be physically returned, destroy) all Background Material and Project Material of another party in its possession or control which it no longer has a licence to use.

16.4

Upon expiration or termination of this Agreement QUT shall repay any Contributions which it has received from the Collaborator which have not been expended or allocated for expenditure prior to the date of termination.

16.5

If this Agreement is terminated under clause 16.2 then the Option will automatically end.

16.6

For the avoidance of doubt, expiration or termination of this Agreement:

(a)

does not affect the operation of any other separate agreement entered by the parties unless it expressly specifies to the contrary in that separate agreement; and

(b)

will be without prejudice to the rights, liabilities or obligations of any party accrued prior to the date of termination including any right to payment or compensation or to obtain damages for breach of this Agreement.

16.7

Clauses 7.2(b), 9, 10, 13, 15 and 16.3 to 16.7 continue to apply after the termination or expiry of this Agreement, except as expressly specified in this Agreement.

GST

17.1

If a supply under this Agreement is subject to GST and GST has not been accounted for in determining the consideration payable for the supply, the supplying party may recover from the receiving party an amount on account of GST. That amount is:

(a)

equal to the value of the supply calculated in accordance with GST law multiplied by the prevailing GST rate; and

(b)

payable at the same time as the recipient is required to pay for the related supply.

NOTICES

18.1

Any notice or other formal communication under this Agreement must be:

(a)

in writing and signed by an authorised representative;

(b)

marked to the attention of the person specified in Schedule 1;

(c)

be delivered to the recipient by hand, pre-paid post, fax or email at the address or number shown in Schedule 1 (or as last notified in writing); and

(d)

will be effective once received, and will be deemed to have been received, if

(1)

if by pre-paid post, on the seventh day after posting;

(2)

if electronically transmitted at the time of successful transmission

PROVIDED that where a notice is received after 5pm on a business day or on a non-business day of the recipient, it will be deemed to be received on the recipient’s next business day.

DISPUTES

19.1	Any dispute relating to this Agreement (Dispute) must, prior to a party initiating litigation (other than for equitable or interlocutory relief), be dealt with as follows:

(a)

the affected party will notify the other parties with details of the Dispute (Dispute Notice) and, within seven (7) days of receiving the Dispute Notice, the parties will negotiate and attempt to resolve the Dispute;

	(b)	if unresolved within thirty (30) days of the Dispute Notice, a nominated member of senior management from each party with authority to fully resolve the dispute (Nominated Persons) will negotiate and attempt to resolve the dispute;

(c)

if unresolved within 30 days of the commencement of the negotiations between the Nominated Persons, any of the affected parties may avail themselves of any legal remedies available in law or equity.

19.2	Nothing in this clause prevents a party from applying to a court for urgent interlocutory relief.

20	GENERAL PROVISIONS

Relationship of parties

20.1	Each party enters into this Agreement as independent contractors. Nothing in this Agreement shall:

(a)

in any way deem an employee of one party to be treated as an employee or the responsibility of another party; or

(b)

create any relationship between the parties amounting to a partnership, agency, trust or joint venture.

Force Majeure

20.2	A party is not liable for any breach of its obligations under this Agreement (other than for any payment obligation) to the extent that the breach resulted from a Force Majeure Event provided that it:

(a)

promptly notifies the other parties (with appropriate details); and

(b)

takes all reasonable steps to work around or reduce the effects of the Force Majeure Event.

If a Force Majeure Event continues for more than sixty (60) days, the party which is not subject to the Force Majeure Event may terminate this Agreement.

Cooperation; No Conflicts; Compliance with Laws

20.3

Each party agrees to execute such agreements, deeds and documents and do or cause to be executed or done all such acts and things as may be reasonably necessary to give effect to this Agreement, including assisting to facilitate any application to register IPRs, confining any rights granted in relation to the IPRs, ensuring where reasonably possible that the Project can continue where a party is withdrawing from the Project and assisting with any GST requirements.

20.4

QUT agrees to provide all information to Quoin necessary to comply with any disclosure requirements mandated by any competent governmental authority (including, if applicable, the US Food and Drug Administration), including any information required to be disclosed in connection with any financial relationships.

20.5	QUT confirms that there is no conflict of interest between parties that would inhibit or affect QUT’s performance under this Agreement. QUT will promptly inform Quoin if any conflict of interest arises during the performance of this Agreement.

20.6	QUT shall not employ, contract, with or retain any person directly or indirectly to perform services under this Agreement if such a person is debarred by a competent government authority (including, if applicable, the US Food and Drug Administration).

No Assignment

20.7	A party must not assign or transfer, any of its rights or obligations in this Agreement to any person without the consent of the other parties, which consent must not be unreasonably withheld or delayed.

Entire Agreement

20.8	This Agreement is the entire agreement between the parties in relation to the management and conduct of the Project. All previous negotiations, understandings, representations or warranties concerning the subject matter of this document are superseded by this document.

Variations

20.9	Any amendment or alterations to this Agreement must be agreed in writing and signed by the parties.

Severability

20.10

If any one or more of the provisions of this Agreement are deemed to be invalid, illegal or unenforceable, then:

(a)

such provisions will be read down or severed and all remaining provisions of this Agreement will remain in full force and effect; and

(b)

such provisions will not invalidate or render unenforceable the remaining provisions of this Agreement.

Governing Law and Jurisdiction

20.11

This Agreement shall be governed by and is to be construed in accordance with the laws applicable in Queensland.

20.12

The parties agree that the courts of Queensland shall have jurisdiction to hear any action in respect of, or arising out of this Agreement.

Legal Costs

20.13

Each party shall be responsible for its own legal and other costs incurred in relation to the preparation of this Agreement.

Execution

20.14

This Agreement may be executed by facsimile or electronic mail and/or in counterparts which will be taken together to constitute one document. The parties agree that execution of this Agreement will occur when each party holds a copy of the Agreement (which may be a facsimile or in electronic format) signed by both parties or signed in counterparts.

Signing Page

EXECUTED as an agreement on the latest of the dates set out below

Executed by Queensland University of Technology

by its duly authorised officer:

/s/ Michael McArdle
Signature of Authorised Representative

Michael McArdle, Executive Director, ORS
Name and Position of Authorised Representative (print)

20/5/2022
Date:

Executed by Quoin Pharmaceuticals, Inc. by its
duly authorised representative:

/s/ Denise Carter
Signature of Authorised Representative

Denise Carter, COO
Name and Position of Authorised Representative (print)

May 20, 2022
Date:

Schedule 1: Notice Details

Queensland University of Technology (QUT)

Contact for Notices:

Address for notices:

By Courier

By Post

By Fax

By Email

Michael McArdle, Executive Director, Office of Research Services

Queensland University of Technology,

Office of Research Services
Level 4, 88 Musk Avenue

Kelvin Grove, Queensland 4059

Office of Research Services
GPO Box 2434, Brisbane Q 4001

07 3138 1304

The Collaborator

Quoin Pharmaceuticals Ltd

Contact for Notices:

Address for notices:

By Courier

By Post

By Email

Michael Myers

CEO

Quoin Pharmaceuticals

42127 Pleasant Forest Court

Ashburn VA 20148

mmyers@quoinpharma.com

Schedule 2 PROJECT DETAILS

PROJECT TITLE

Selection of a lead VLA-4 inhibitor for entry into a Scleroderma clinical development program.

PROJECT EXPIRATION DATE:

31/12/2023 (assuming a 01/07/2022 start date)

PROJECT SUMMARY

The overall goal of the research plan is to select a lead VLA-4 inhibitor for entry into a Scleroderma clinical development program. The specific aims of the program are:

	1.	In vitro and in vivo compound screening to determine the activity and pharmacokinetics of the three novel compounds and select a lead compound.

	2.	Determine pre-clinical efficacy of VCAM-1:VLA-4 blockade in a model of Scleroderma.

	3.	In vivo assessment of the pharmacodynamics of the lead compound to define the dose-response relationship for Scleroderma.

Assessment of non-GLP PK and Tox for the lead

SPECIFIED PERSONNEL

A/Professor Tony Kenna and an RA will carry out the research.

Schedule 3 contributions

CONTRIBUTIONS:

[****]

CASH CONTRIBUTION INVOICE SCHEDULE:

[****]

Financial Contact Details:

QUT Financial Contact

[****]

Quoin Financial Contact

Michael Myers

CEO

Quoin Pharmaceuticals

42127 Pleasant Forest Court

Ashburn VA 20148

mmyers@quoinpharma.com

Schedule 4 BACKGROUND MATERIAL AND CONFIDENTIAL INFORMATION

[****]

Exhibit 10.2

WAIVER AGREEMENT

This WAIVER AGREEMENT (the "Agreement"), dated as of June 6, 2022, is made by and between Quoin Pharmaceuticals Ltd., an Israeli company, with headquarters located at Azrieli Center, Round Tower, 30th Floor, 132 Menachem Begin Blvd, Tel Aviv, 6701101 (the "Company" or “PublicCo”), Quoin Pharmaceuticals Inc., a Delaware corporation (“PrivateCo”), and the investor listed on the signature page attached hereto (the "Holder"). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the SPA (as defined below).

A. Pursuant to that certain Securities Purchase Agreement (as amended, the "SPA") dated as of March 24, 2021 by and between the Company, PrivateCo and the Holder, the Company agreed, among other things, that, pursuant to Section 5(n)(ii) of the SPA, until the Trigger Date, it will not file any registration statement, or any amendment or supplement thereto, other than Exempt Registration Statements or cause any registration statement other than the Exempt Registration Statements to be declared effective by the SEC (collectively, the "Registration Statement Restriction"); and

B. The Company wishes for the Holder, and the Holder hereby agrees, to waive the Registration Statement Restriction upon the terms and conditions set forth herein.

NOW THEREFORE, in consideration of the foregoing mutual premises and the covenants and agreements hereinafter set forth, and for other good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

Limited Waiver of Registration Statement Restriction. The Holder hereby waives the Registration Statement Restriction solely with respect to a single registration statement on Form F-3 to be filed by the Company on or prior to June 30, 2022 for the primary shelf offering of ordinary shares, no par value, represented by the ADSs, with each ADS representing 400 ordinary shares, warrants to purchase ordinary shares represented by ADSs, subscription rights, debt securities consisting of debentures, notes or other evidences of indebtedness, and units comprised of, or other combinations of, the foregoing securities, in one or more offerings, with an aggregate offering price not exceeding $100,000,000, including, but not limited to, an “at-the-market” offering. For the avoidance of doubt, the waiver contained in this Section 1 is limited to the Registration Statement Restriction and does not extend to the Company's restriction set forth in Section 5(n)(ii) of the SPA on entering into, effecting or consummating a Subsequent Placement, a transaction under, any agreement, including, but not limited to, an equity line of credit or “at-the-market” offering, whereby the Company may issue securities at a future determined price or on being a party to any solicitations, negotiations or discussions with regard to the foregoing.

Representations and Warranties. The Holder represents and warrants to the Company and PrivateCo that the Holder, and each of the Company and PrivateCo represents and warrants to the Holder that each of the Company and PrivateCo, as of the date hereof: (i) is an entity duly organized and validly existing under the laws of the jurisdiction of its formation, has the requisite power and authority to execute and deliver this Agreement and to carry out and perform all of its obligations under the terms of this Agreement; (ii) has duly executed and delivered on behalf of the applicable party this Agreement. The Holder and each of the Company and PrivateCo represents and warrants that (a) this Agreement constitutes the valid and legally binding obligation of the Holder and each of the Company and PrivateCo, as applicable, enforceable against such person in accordance with its terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies; and (b) the execution, delivery and performance by the applicable party of this Agreement and the consummation by such person of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of such person, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such person is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such person, except in the case of clause (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such person to perform its obligations hereunder.

Disclosure of Transactions and Other Material Information. The Company shall file a report on Form 6-K (the "6-K Filing") on or before 8:30 a.m., New York City time, on June 6, 2022, in the form required by the 1934 Act, relating to the transactions contemplated by this Agreement and attaching a form of this Agreement (including, without limitation, all schedules and exhibits to such agreement, if any) as an exhibit to such filing. From and after the filing of the 6-K Filing with the SEC, the Holder shall not be in possession of any material, nonpublic information received from the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees or agents, that is not disclosed in the 6-K Filing. In addition, effective upon the filing of the 6-K Filing, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors, Affiliates, employees or agents, on the one hand, and the Holder or any of its Affiliates, on the other hand, shall terminate and be of no further force or effect. The Company shall not, and shall cause each of its subsidiaries and its and each of their respective officers, directors, Affiliates, employees and agents, not to, provide the Holder with any material, nonpublic information regarding the Company or any of its subsidiaries from and after the date hereof without the express prior written consent of the Holder. The Company understands and confirms that the Holder will rely on the foregoing representations in effecting transactions in securities of the Company.

Miscellaneous. This Agreement may be executed in any number of counterparts, which together shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. In the event that any provision of this Agreement is found to be void or invalid, then such provision shall be deemed to be severable from the remaining provisions of this Agreement, and it shall not affect the validity of the remaining provisions, which provisions shall be given full effect as if the void or invalid provision had not been included herein so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties hereto as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). The terms and provisions of this Agreement shall inure to the benefit of and be binding upon the permitted successors and assigns of the parties. This Agreement constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and supersedes in their entirety all prior negotiations, understandings and agreements with respect to such subject matter, whether written or oral. There are no restrictions, promises, warranties or undertakings with respect to the subject matter hereof, other than those set forth or referred to herein. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York (without giving effect to the conflict of laws principles thereof). The courts of the State of New York shall have exclusive jurisdiction to resolve any and all disputes that may arise under this Agreement. Any amendments or modifications hereto must be executed in writing by all parties. Each party hereto shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement. The Company shall reimburse the Holder for its reasonable legal fees and expenses actually incurred in connection with the preparation and negotiation of this Agreement and transactions contemplated thereby, by paying any such amount to Schulte Roth & Zabel LLP within two (2) Business Days of receiving the invoice of Schulte Roth & Zabel LLP by wire transfer of immediately available funds in accordance with the written instructions of Schulte Roth & Zabel LLP.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused their respective signature pages to this Agreement to be duly executed as of the date first written above.

COMPANY:

QUOIN PHARMACEUTICALS LTD.

By:	/s/ Dr. Michael Myers
	Name:	Dr. Michael Myers
	Title:	Chief Executive Officer

PRIVATECO:

QUOIN PHARMACEUTICALS INC.

By:	/s/ Dr. Michael Myers
	Name:	Dr. Michael Myers
	Title:	Chief Executive Officer

IN WITNESS WHEREOF, the parties have caused their respective signature pages to this Agreement to be duly executed as of the date first written above.

HOLDER:

ALTIUM GROWTH FUND, LP

By:	/s/ Mark Gottlieb
	Name:	Mark Gottlieb
	Title:	COO